|
Synonyms: compound 10a [PMID: 23301703] | GZD-824 | GZD824 | HQP-1351 | HQP1351
olverembatinib is an approved drug (China (2021))
Compound class:
Synthetic organic
Comment: Olverembatinib (HQP1351; formerly GZD824) is a novel third-generation, orally bioavailable kinase inhibitor with activity against a broad spectrum of Bcr-Abl mutants including the T315I resistance mutation [3-4]. The chemical structure for GZD824 is identical to that submitted to the WHO for the INN olverembatinib. GZD824's structure and use was first claimed in a patent from the Guangzhou Institute of Biomedicine and Health [5], but it is now being progressed by Ascentage Pharma and HealthQuest Pharma.
SARS-CoV-2: Olverembatinib has been reported to inhibit human PBM cytokine release (in vitro) as induced by the SARS-CoV-2 omicron variant [1]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
For advanced searching click here to open chemical structure editor
